BioStock: EU gene therapy approval positive for CombiGene

Recently, PTC Therapeutics was granted marketing authorisation by the European Commission for the gene therapy Upstaza for the treatment of a rare genetic disease. This is good news for Swedish CombiGene, whose gene therapy CG01 for the treatment of epilepsy, which was outlicensed to Spark Therapeutics in the autumn of 2021, like Upstaza, is intended to be administered directly into the brain of patients. BioStock reached out to CombiGene’s CEO Jan Nilsson for a comment.

Read the full interview with Jan Nilsson at biostock.se:

https://www.biostock.se/en/2022/08/eu-gene-therapy-approval-positive-for-combigene/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/